177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This phase 1 dose-escalation and dose-expansion study is designed to evaluate the safety and
tolerability of olaparib in combination with 177Lutetium-Prostate Specific Membrane Antigen
(177 Lu-PSMA) in patients with metastatic castration resistant prostate cancer (mCRPC).